Education
About Us
Working with TipRanks
Follow Us
BioGaia AB Class B (SE:BIOG.B)
:BIOG.B
BIOG.B Stock Chart & Stats
kr105.60
-kr1.50(-1.25%)
At close: 4:00 PM EST
kr105.60
-kr1.50(-1.25%)
Day’s Range― - ―
52-Week Rangekr93.20 - kr133.50
Previous CloseN/A
Volume64.55K
Average Volume (3M)124.05K
Market Cap
kr10.51B
Enterprise Valuekr9.43B
Total Cash (Recent Filing)kr801.31M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)31.3
Beta0.49
Next Earnings
May 13, 2026EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend Yield1.95%
Share Statistics
EPS (TTM)0.98
Shares Outstanding98,497,170
10 Day Avg. Volume90,103
30 Day Avg. Volume124,054
Financial Highlights & Ratios
PEG Ratio-6.22
Price to Book (P/B)8.17
Price to Sales (P/S)6.98
P/FCF Ratio35.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthMulti-year revenue expansion demonstrates durable demand for BioGaia's probiotic products and successful commercial distribution. A steady top-line trend supports capacity to invest in R&D, partnerships and global expansion, reducing execution risk over the next several quarters.
High Gross MarginsSustained gross margins near the mid-70% range indicate strong product economics and pricing power for its probiotic strains. High gross margins provide structural room to absorb SG&A or R&D increases and support long-term operating profitability even if unit costs rise.
Very Conservative Balance SheetNegligible leverage and zero reported debt in 2025 materially lower financial risk and preserve strategic optionality. This balance sheet strength supports resilience in downturns, funds partnership investments or targeted M&A, and sustains dividend or buyback flexibility.
Bears Say
Margin Compression Since 2022A near 12-point drop in net margin over a three-year span signals rising cost pressures or increased spending intensity that erode earnings power. If structural, weaker margins limit retained earnings, constrain reinvestment and raise sensitivity to slower sales growth.
Weakened Free Cash Flow / Cash Conversion PressureDeclining FCF and lower operating cash versus prior years reduce financial flexibility to fund growth or return capital. Persistent cash conversion deterioration can indicate working capital strain or higher capex and raises risk that reported earnings are less cash-backed.
Decline In Shareholders' EquityA sizable reduction in equity over two years weakens the capital cushion and may reflect payouts, write-downs or accumulated deficits. Lower equity constrains balance-sheet capacity for larger investments or absorbing shocks, increasing dependence on operational cash flow.
BioGaia AB News
BIOG.B FAQ
What was BioGaia AB Class B’s price range in the past 12 months?
BioGaia AB Class B lowest stock price was kr93.20 and its highest was kr133.50 in the past 12 months.
What is BioGaia AB Class B’s market cap?
BioGaia AB Class B’s market cap is kr10.51B.
When is BioGaia AB Class B’s upcoming earnings report date?
BioGaia AB Class B’s upcoming earnings report date is May 13, 2026 which is in 82 days.
How were BioGaia AB Class B’s earnings last quarter?
BioGaia AB Class B released its earnings results on Feb 12, 2026. The company reported kr0.98 earnings per share for the quarter, beating the consensus estimate of kr0.8 by kr0.18.
Is BioGaia AB Class B overvalued?
According to Wall Street analysts BioGaia AB Class B’s price is currently Overvalued.
Does BioGaia AB Class B pay dividends?
BioGaia AB Class B pays a Notavailable dividend of kr6.9 which represents an annual dividend yield of 1.95%. See more information on BioGaia AB Class B dividends here
What is BioGaia AB Class B’s EPS estimate?
BioGaia AB Class B’s EPS estimate is 0.84.
How many shares outstanding does BioGaia AB Class B have?
BioGaia AB Class B has 98,497,170 shares outstanding.
What happened to BioGaia AB Class B’s price movement after its last earnings report?
BioGaia AB Class B reported an EPS of kr0.98 in its last earnings report, beating expectations of kr0.8. Following the earnings report the stock price went down -6.749%.
Which hedge fund is a major shareholder of BioGaia AB Class B?
Currently, no hedge funds are holding shares in SE:BIOG.B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioGaia AB Class B
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylorithe gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---